Jeremy Bender, Day One Biopharmaceuticals CEO
June 18, 2024 10:45 AM EDT
Deals
China

Day One en­ters ADC field, go­ing af­ter a tar­get that once at­tract­ed Ab­b­Vie and now Gen­mab

Kyle LaHucik

Senior Reporter

Short­ly af­ter se­cur­ing its first FDA ap­proval and bag­ging $108 mil­lion from a pri­or­i­ty re­view vouch­er sale, Day One …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times